Table 3.

aHUS associated with systemic disease

Patient	Age (years), gender	Systemic disease	Treatment before eculizumab	PE no. of sessions	Eculizumab (duration, no. of doses)	Time from aHUS to eculizumab (days)	Highest SCr (mg/dL) HD (Yes/No)	Latest SCr (mg/dL)	Follow-up (months)
16	51, female	SLEa	CS + Cyc + Rtx + PE	10	4 weeks, 4	31	4.2 Yes	Dialysis	0.9
17	16, female	SLEa	CS + MMF	–	10 weeks, 7	1	7.1 Yes	Dialysis	4.2
18	52, female	SLE	CS + Cyc + PE	27	2 weeks, 2	38	6.4 Yes	4.2	4.0
19	63, male	Scleroderma	CS + Cyc + PE	10	6 weeks, 5	55	4.9 No	Dialysis	12.9
20	56, male	Scleroderma	CS + Mtx + PE	10	8 weeks, 6	25	3.7 No	3.4	4.3
21	52, male	EGPA	CS + Cyc	–	16 weeks, 10	5	3.5 No	2.3	4.3
22	49, male	EGPA	CS + Cyc + PE	2	130 weeks, ongoing	15	6.5 Yes	Dialysis	29.5
23	38, male	Primary APS	–	–	14 weeks, 9	1	9.5 Yes	3.4	4.4

^aaHUS, atypical haemolytic uraemic syndrome; APS, Antiphospholip syndrome; CS, corticosteroids; Cyc, cyclophosphamide; EGPA, eosinophilic granulomatosis with polyangiitis; HD, Hemodialysis (Yes/No); Mtx, methotrexate; MMF, mycophenolate mofetil; ND, not done; PE, plasma exchange; Rtx, rituximab; SCr, serum creatinine; SLE, systemic lupus erythematosus.